Copyright
©2014 Baishideng Publishing Group Co.
World J Nephrol. May 6, 2014; 3(2): 16-23
Published online May 6, 2014. doi: 10.5527/wjn.v3.i2.16
Published online May 6, 2014. doi: 10.5527/wjn.v3.i2.16
Class | Name | Light microscopy | Immunofluorescence | ||
I | Minimal mesangial LN | Normal | Mesangial immune deposits | ||
II | Mesangial proliferative LN | Mesangial hypercellularity or mesangial matrix expansion | Mesangial immune deposits | ||
III | Focal LN | A | Active lesions | Segmental, or global glomerulonephritis (< 50% of glomeruli) | Diffuse subendothelial immune deposits |
A/C | Active and chronic lesions | ||||
C | Chronic lesions | ||||
IV | Diffuse LN | A | Active lesions | Segmental, or global glomerulonephritis LN (> 50% glomeruli) | Diffuse subendothelial immune deposits |
A/C | Active and chronic lesions | ||||
C | Chronic lesions | ||||
V | Membranous LN | Global or segmental subepithelial immune deposits | |||
VI | Advanced sclerosing LN | LN (> 90% globally Sclerosed glomeruli without residual activity) |
Stage of disease | Blood pressure | Urinalysis | Protein/creatinine ratio | Serum creatinine | C3/C4 level | Anti-DNA |
Active nephritis at onset of treatment | 1 | 1 | 1 | 1 | 2 | 3 |
Previous active nephritis, none currently | 3 | 3 | 3 | 3 | 3 | 6 |
No prior or current nephritis | 3 | 6 | 6 | 6 | 6 | 6 |
- Citation: Sinha R, Raut S. Pediatric lupus nephritis: Management update. World J Nephrol 2014; 3(2): 16-23
- URL: https://www.wjgnet.com/2220-6124/full/v3/i2/16.htm
- DOI: https://dx.doi.org/10.5527/wjn.v3.i2.16